谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

288PDPERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

J Huober,P Weder,C Veyret,B. Thürlimann,A Xyrafas,L Vanlemmens,S Guiu,Etienne Brain,J Grenier,F Dalenc,C Levy,A M Savoye,Andreas Müller, V Membrez-Antonioli, M A Gerard,J Lemonnier,H Hawle,Epie Boven,Hervé Bonnefoi

ANNALS OF ONCOLOGY（2018）

引用 5|浏览89
关键词
pertuzumab,chemotherapy,pernetta,cancer,non-comparative
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要